Eli Lilly and Company (NYSE:LLY) Trading Up 2.2% After Dividend Announcement

Key Points

• Dividend: Shares rose 2.2% after Eli Lilly declared a $1.73 quarterly dividend (payable June 10; ex‑dividend and record date May 15), representing a $6.92 annualized payout and a ~0.7% yield with a 24.6% payout ratio.
• Analyst sentiment: Multiple firms have raised price targets and the consensus rating is a Moderate Buy with a $1,217.59 average target; the company trades with a market cap near $934B and a P/E around 35.
• Operational backdrop: Eli Lilly posted a strong Q1 beat (EPS $8.55 vs $6.97 estimate; revenue $19.8B, +55.5%) powered by GLP‑1 growth and a strong Foundayo launch, but faces headline risks from an FDA liver‑failure report and competitive pressure from Novo Nordisk.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price was up 2.2% on Tuesday after the company announced a dividend. The company traded as high as $992.80 and last traded at $989.0170. Approximately 2,933,279 shares changed hands during trading, a decline of 8% from the average daily volume of 3,189,931 shares. The stock had previously closed at $967.93.The newly announced dividend which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company's dividend payout ratio is presently 24.58%.

Analysts Set New Price Targets

Several research analysts have weighed in on LLY shares. CICC Research upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a "neutral" rating in a report on Wednesday, February 11th. Barclays upped their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Monday. TD Cowen upped their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Thursday, January 29th. Daiwa Securities Group upped their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $1,344.00 target price on shares of Eli Lilly and Company in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,217.59.

Eli Lilly and Company Stock Performance

The firm has a market capitalization of $934.44 billion, a PE ratio of 35.13, a P/E/G ratio of 1.13 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company's fifty day simple moving average is $947.05 and its 200 day simple moving average is $987.36.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company's revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 33.79 EPS for the current fiscal year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo (oral GLP‑1) has had a strong launch with broad pharmacy access, growing prescribers and early patient momentum — supporting sales upside for Lilly's obesity franchise. Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
• Positive Sentiment: Omvoh (mirikizumab‑mrkz) posted durable 4‑year disease‑clearance data in ulcerative colitis (63.5% sustaining clearance at 4 years), strengthening long‑term franchise value in immunology. Lilly's Omvoh is the first and only IL-23p19 to demonstrate durable disease clearance through four years
• Positive Sentiment: Strong Q1 results and GLP‑1 dominance (reports of ~60% GLP‑1 market share and large Mounjaro revenue growth) reinforce the company's revenue trajectory and FY guidance upside. Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (including Wolfe Research, Barclays and others) are boosting sentiment and providing upside to the consensus valuation. Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report
• Neutral Sentiment: The board declared a $1.73 quarterly dividend (payable June 10), a modest return to shareholders that supports income investors but is unlikely to materially move valuation. Lilly declares second-quarter 2026 dividend
• Negative Sentiment: FDA adverse‑event reports show at least one liver‑failure case linked to Foundayo; the safety flag triggered a short pullback in shares and remains a headline risk until clarified. FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
• Negative Sentiment: Competitive pressure from Novo Nordisk (Wegovy pill momentum and potential price competition) and industry pricing dynamics could compress GLP‑1 margins over time. Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises
• Negative Sentiment: Large insider/institutional sell activity noted in datasets may create near‑term selling pressure and is being watched by investors. Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares in the last quarter. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $30,000. Finally, 10Elms LLP lifted its holdings in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.